Topics of the Congress will focus on various aspects of physical activity and nutrition, including psychological well-being, special groups (children, adolescents, elderly, athletes, people with disabilities), measurement issues, chronic diseases, public health, weight management, recreation, and public policy. For more information, visit www.ipanhec2011.org. Deadline for submitting material for the People and Events section is the first of the month, 3 months before the date of the issue (eg, May 1 for the August issue). Publication of an educational event is not an endorsement by the Association of the event of sponsor.

Send material to: Ryan Lipscomb, Department Editor, Journal of the American Dietetic Association, 120 S. PD0332991 chemical structure Riverside Plaza, Suite 2000, Chicago, IL 60606; [email protected]; 312/899-4829; or fax, 312/899-4812. Florence Labelle Thoke, April 2011, click here was a member of the American Dietetic Association and the California Dietetic Association. After graduating from Michigan State University with a Bachelor of Science Degree in Dietetics, she began

her career as a dietitian in Detroit at the Stouffer’s Top of the Flame Restaurant and continued with the Stouffer’s Company in Chicago, where she worked until 1986. Thoke then moved to California and continued her professional career at the Eisenhower Medical Center until her retirement. “
“The article in the June 2011 issue of the Journal on the American Dietetic Association’s 2011-2012 Board of Directors (pp 942-946) misstated information about Barbara J. Ivens. Her identification should have read: Barbara J. Ivens, MS, RD, FADA, Omaha,

NE. “
“Treatment of patients with type 2 diabetes (T2D) aims to reduce insulin MRIP resistance and enhance beta-cell secretion through lifestyle modification and use of metformin, followed by the combination of other oral antidiabetic drugs (OADs). Nevertheless, due to the progressive deterioration in glycaemic control, insulin therapy is often required to achieve glycaemic goals [1]. Lowering glucose levels to the recommended HbA1c level <7.0% is associated with reduction in microvascular complications and, if achieved in a timely manner after diagnosis, may also improve macrovascular outcomes [1]. Sitagliptin, a widely used, highly selective oral dipeptidyl peptidase-4 (DPP-4) inhibitor, can be used in dual or triple therapy when glycaemic control is not attained with metformin [1] and [2]. Although DPP-4 inhibitors are weight-neutral and have a low hypoglycaemia risk, they are associated with modest glucose-lowering activity (HbA1c reduction 0.5–0.9%) [3] and [4]. In a head-to-head comparison, significantly better glycaemic control was achieved with insulin glargine versus sitagliptin, both with metformin, in insulin-naïve patients with T2D, although symptomatic hypoglycaemia was also significantly greater with this insulin-based regimen [5].